Suzhou Inces Intelligent Technology

About Suzhou Inces Intelligent Technology

Established in 2017, Suzhou Inces Intelligent Technology Co., Ltd. (Inscinstech) operates as a specialized provider of comprehensive solutions for the biopharmaceutical CMC (Chemistry, Manufacturing, and Controls) sector, covering upstream and downstream processes as well as laboratory analysis. The company was founded by Li Dawei, who currently serves as General Manager. The core leadership team comprises individuals with backgrounds in leading biopharmaceutical enterprises.

Inscinstech's business model centers on the research, development, production, and sale of high-quality biological separation equipment and chemical analysis instruments. Its revenue is generated through the sale of these products to a diverse client base that includes biotech companies, universities, and scientific research institutes involved in antibodies, vaccines, cell and gene therapy (CGT), nucleic acid drugs, and in-vitro diagnostics (IVD). The company has established a significant market presence, serving over a thousand domestic and international clients. To support its operations, Inscinstech has set up two R&D centers and a production and manufacturing base spanning over 10,000 square meters in Suzhou, enabling the independent production of core components. Additionally, the company has marketing and service centers in Suzhou, China, and Los Angeles, USA, along with R&D facilities in Suzhou and Boston, USA.

The company's product portfolio includes protein purification systems, large-scale oligonucleotide synthesizers, chromatography high-pressure pumps, and liquid chromatographs. One of its notable products, the Unique AutoPure protein purification system, is designed for the purification of various substances, from micrograms to grams, including proteins, peptides, and nucleic acids. These products find applications in the downstream processing and separation of biopharmaceutical products. The company has achieved several financing rounds, including a Pre-A round in April 2021, an A round of nearly ten million USD in October 2021, and a B+ round of nearly 150 million RMB in January 2023, with investors such as Qiming Venture Partners, Yida Capital, and Matrix Partners China.